FDA Orange Book: Where to Find Patent Expiration Dates for Generic Drug Entry

When a brand-name drug’s patent expires, it opens the door for cheaper generic versions to hit the market. But figuring out exactly when that happens isn’t as simple as checking a calendar. For pharmacists, generic drug manufacturers, and even patients waiting for lower-cost options, the FDA Orange Book is the go-to source for accurate patent expiration dates. It’s not just a list-it’s a legal roadmap that determines when generics can legally launch.

What the FDA Orange Book Actually Is

The FDA Orange Book, officially called Approved Drug Products with Therapeutic Equivalence Evaluations, has been around since 1985. It was created under the Hatch-Waxman Act to balance innovation and access. The law gave drug companies extra patent time to make up for delays in FDA approval, while also setting a clear path for generics to enter the market after those protections end.

It’s not a marketing tool. It’s a regulatory database. Every approved small-molecule drug in the U.S. that has patents or exclusivity is listed here. That includes brand-name drugs like Brilinta, Lipitor, or Humira. Each entry shows the patent numbers, their expiration dates, and any regulatory exclusivity periods that delay generic competition.

You won’t find this in a pharmacy brochure or on a drug package. You have to go directly to the FDA’s website to access it. And if you’re trying to time a generic launch or understand why a drug still has no competitors, this is where you start.

How to Find Patent Expiration Dates in the Electronic Orange Book

The FDA stopped printing the Orange Book in 1999. Today, it’s all online. The current version, called the Electronic Orange Book, is updated daily. Here’s how to find what you need:

1. Go to https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm (this link is for reference; no hyperlinks are allowed in final output).
2. Search by the drug’s brand name, active ingredient, or application number. For example, if you’re looking up Brilinta, type in “ticagrelor,” the active ingredient.
3. Click on the application number linked to the drug you’re researching.
4. At the bottom of the drug’s page, click “View.” This opens the full patent and exclusivity listing.

Each patent listed will show:

• The patent number
• The expiration date in MMM DD, YYYY format (like July 9, 2021)
• A patent use code (like U-123), which tells you what specific medical use the patent covers
• Whether the patent owner requested to delist it (a red flag that the patent may be invalid or unenforceable)

For example, Brilinta’s listing shows multiple patents expiring between 2018 and 2021. But the actual market entry for generics was blocked longer because of exclusivity protections, not patents. That’s why you need to check both.

Why Patent Expiration Dates Can Be Misleading

Don’t assume the date you see is the final word. There are three big reasons why:

1. Patent Term Extensions (PTE)
If the FDA took too long to approve a drug, the patent holder can apply for extra time-up to five years-to make up for it. The Orange Book includes these extensions. But they’re not always obvious. A patent originally set to expire in 2020 might now show 2025 because of PTE.

2. Pediatric Exclusivity
If a company does extra studies on how the drug works in children, they get a six-month bonus exclusivity period. This doesn’t create a new patent. Instead, it gets tacked onto every existing patent and exclusivity period for that drug. So you’ll see the same patent listed twice: once with the original date, and once with the six-month extension. Many people miss this and think there’s a new patent.

3. Early Patent Expirations Patents can die before their listed date. Why? Because patent owners have to pay maintenance fees every few years. If they don’t, the patent expires early. The FDA doesn’t update the Orange Book to reflect these early expirations. A 2023 study found that 46% of patents listed in the Orange Book had already expired early due to unpaid fees. That means the database shows a patent as active when it’s not.

If you’re planning to launch a generic, you can’t rely on the Orange Book alone. You need to cross-check with the USPTO Patent Center database to see if maintenance fees were paid. Otherwise, you might wait for a patent that’s already dead.

How to Use the Data Files for Bulk Analysis

If you’re a manufacturer, researcher, or analyst working with dozens of drugs, the web interface won’t cut it. The FDA provides downloadable data files updated every day at https://www.fda.gov/drugs/drug-approval-applications-das/orange-book-data-files (this link is for reference; no hyperlinks are allowed in final output).

These files are CSV or tab-delimited and include columns like:

• Product No - The unique ID for each drug product
• Patent No - The actual patent number
• Patent Expiration - The date in MM/DD/YYYY format
• Drug Substance Flag - Shows if the patent covers the active ingredient (Y) or just the formulation (null)
• Delist Requested Flag - Y means the company asked to remove the patent (a major signal)
• Patent Use Code - The U-code that links to the specific medical use

These files let you sort, filter, and compare hundreds of drugs at once. You can find all drugs with patents expiring in 2026, or see which ones have delisting requests-key intel for predicting market shifts.

What You Shouldn’t Trust

Third-party websites, patent databases, and even some pharmacy software often pull data from the Orange Book-but they don’t update daily. Some only refresh once a month. That’s dangerous. A patent could be delisted on Monday, and by Friday, you’re still seeing it as active on a slow-updating site.

Also, don’t confuse exclusivity with patents. Exclusivity is a separate FDA protection that doesn’t come from a patent. It can delay generics even if all patents have expired. For example, a drug might have no active patents, but still be protected by three years of exclusivity because it was a new use. The Orange Book lists both, but they’re different.

Why This Matters to Everyone

If you’re a patient, this affects your out-of-pocket costs. If you’re a pharmacist, it tells you when generics will be available to prescribe. For generic manufacturers, this data is the foundation of their business model. A single patent expiration can mean billions in revenue.

In 2023, the FDA updated the Orange Book to improve transparency after the Orange Book Transparency Act of 2020. Filters were added, search became faster, and the “View All Patents” button now shows every patent linked to a drug-no more hidden listings.

Still, the system isn’t perfect. The FDA admits it doesn’t retroactively correct old entries. That means older drugs might have outdated or incomplete data. Always check the most recent version. And if you’re making decisions based on this, verify with the USPTO and monitor for delisting requests. Those are the real signals that a patent is no longer a barrier.

Quick Reference: What to Look For

• Patent Expiration Date: The date the patent legally ends. Look for this first.
• Patent Use Code: Helps you know if the patent covers the drug’s use (not just its form).
• Delist Requested Flag: If it says “Y,” the patent owner may have given up on enforcement.
• Exclusivity Expiration: Separate from patents. Can block generics even if patents are gone.
• Drug Substance Flag: “Y” means the patent covers the active ingredient-this is the most important type.

Frequently Asked Questions

Next Steps

If you’re looking to predict when generics will enter the market:

• Start with the FDA Orange Book for the official expiration dates.
• Check the USPTO Patent Center for maintenance fee payments-this tells you if the patent is still alive.
• Look for “Y” in the Delist Requested Flag. That’s often the first sign a company is stepping back.
• Don’t ignore exclusivity. Even with no patents, a drug might be protected for years.

The path to generic access isn’t just about dates-it’s about reading between the lines. The Orange Book gives you the map. But you need to know what the symbols mean.